Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Linagliptin

    Client Email Product

    Linagliptin

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    84
    US DMFs Filed

    US DMFs Filed

    28
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    3
    Other Certificates

    Other Certificates

    12
    Other Suppliers

    Other Suppliers

    68
    API REF. PRICE (USD / KG)
    2,666

    API Market Place

    23
    INTERMEDIATES
    71
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    42
    Europe

    Europe

    22
    Canada

    Canada

    4
    Australia

    Australia

    2
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    26
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    7,844.00

    Annual Reports

    2,154.00

    FDF Market Place

    6
    EXCIPIENTS
    96
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    241

    USFDA Exclusivities

    12
    DIGITAL CONTENT

    Blog #PharmaFlow

    4

    News

    59
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    21
    SERVICES
    1
    left grey arrow
    right gray arrow
    • TABLET;ORAL - 5MG
    • TABLET;ORAL - 2.5MG;1GM
    • TABLET;ORAL - 2.5MG;500MG
    • TABLET;ORAL - 2.5MG;850MG
    • TABLET;ORAL - 10MG;5MG
    • TABLET;ORAL - 25MG;5MG
    Full View ScreenFull Screen View
    Lupin acquires two diabetes brands from Boehringer Ingelheim
    Lupin acquires two diabetes brands from Boehringer Ingelheim

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-acquires-two-diabetes-brands-from-boehringer-ingelheim/articleshow/102841038.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    19 Aug 2023
    Share Share
    Sun's Generic Empagliflozin, Linagliptin Receives Approval in the U.S.
    Sun's Generic Empagliflozin, Linagliptin Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212339

    FDA
    12 Jun 2023
    Share Share
    Sun's Generic Linagliptin, Metformin HCL Receives Receives Approval in the U.S.
    Sun's Generic Linagliptin, Metformin HCL Receives Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211921

    FDA
    10 May 2023
    Share Share
    Zydus' Generic Linagliptin Receives Approval in the U.S.
    Zydus' Generic Linagliptin Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208448

    FDA
    30 Mar 2023
    Share Share
    Zydus' Generic Linagliptin, Metformin Hydrochloride Receives Approval in the U.S.
    Zydus' Generic Linagliptin, Metformin Hydrochloride Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208449

    FDA
    30 Mar 2023
    Share Share
    Torrent enters into co-marketing partnership with Boehringer Ingelheim India
    Torrent enters into co-marketing partnership with Boehringer Ingelheim India

    https://www.indianpharmapost.com/news/torrent-enters-into-co-marketing-partnership-with-boehringer-ingelheim-india-13452

    INDIANPHARMAPOST
    15 Dec 2022
    Share Share
    PIII trial demonstrated Jardiance show reduction in blood sugar
    PIII trial demonstrated Jardiance show reduction in blood sugar

    https://www.businesswire.com/news/home/20221207005405/en

    BUSINESSWIRE
    07 Dec 2022
    Share Share
    Pricing authority caps rates of key diabetes drugs
    Pricing authority caps rates of key diabetes drugs

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pricing-authority-caps-rates-of-key-diabetes-drugs/articleshow/93785721.cms

    Teena Thacker ECONOMIC TIMES
    25 Aug 2022
    Share Share
    Alkem's Generic Empagliflozin, Linagliptin Receives Approval in the U.S.
    Alkem's Generic Empagliflozin, Linagliptin Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212366

    FDA
    09 Aug 2022
    Share Share
    Sunshine's Generic Linagliptin Receives Approval in the US
    Sunshine's Generic Linagliptin Receives Approval in the US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208335

    FDA
    31 Aug 2021
    Share Share
    Sunshine's Generic Linagliptin & Metformin HCl Receives Approval in the US
    Sunshine's Generic Linagliptin & Metformin HCl Receives Approval in the US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208336

    FDA
    30 Aug 2021
    Share Share
    Dr. Reddy's Labo`s Generic Linagliptin;Metformin HCl Receives Approval In US
    Dr. Reddy's Labo`s Generic Linagliptin;Metformin HCl Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208427

    FDA
    06 Feb 2021
    Share Share
    Zydus Cadila gets tentative nod from USFDA to market diabetes drug
    Zydus Cadila gets tentative nod from USFDA to market diabetes drug

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-tentative-nod-from-usfda-to-market-diabetes-drug/articleshow/78927846.cms

    ECONOMICTIMES
    29 Oct 2020
    Share Share
    Lupin Ltd`s Generic Empagliflozin;Linagliptin Receives Tentative Approval In US
    Lupin Ltd`s Generic Empagliflozin;Linagliptin Receives Tentative Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212335

    FDA
    30 Jul 2020
    Share Share
    Lupin gets tentative nod for Empagliflozin and Linagliptin tablets
    Lupin gets tentative nod for Empagliflozin and Linagliptin tablets

    https://www.business-standard.com/article/news-cm/lupin-gets-tentative-nod-for-empagliflozin-and-linagliptin-tablets-120072400206_1.html#:~:text=Lupin%20announced%20that%20it%20has,hours%20yesterday%2C%2023%20July%202020.

    BUSINESS-STANDARD
    23 Jul 2020
    Share Share
    MSN Labs Generic Empagliflozin;Linagliptin Receives Approval In US
    MSN Labs Generic Empagliflozin;Linagliptin Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212359

    FDA
    10 Jul 2020
    Share Share
    FDA fast-tracks BI, Lilly's Jardiance in chronic heart failure
    FDA fast-tracks BI, Lilly's Jardiance in chronic heart failure

    https://www.fiercepharma.com/pharma/bi-eli-lilly-s-jardiance-nabs-fda-fast-track-for-chronic-heart-failure-studies

    K. Blankenship FIERCE PHARMA
    26 Jun 2019
    Share Share
    Lilly, Boehringer's DPP-4 drug Tradjenta ties rival in heart safety study
    Lilly, Boehringer's DPP-4 drug Tradjenta ties rival in heart safety study

    https://www.fiercepharma.com/pharma/ada-lilly-bi-s-tradjenta-ties-generic-rival-heart-safety-study

    Carly Helfand FIERCE PHARMA
    11 Jun 2019
    Share Share
    US FDA Accepts NDA for Triple Combination Tablet for Adults with Type 2 Diabetes
    US FDA Accepts NDA for Triple Combination Tablet for Adults with Type 2 Diabetes

    https://www.prnewswire.com/news-releases/us-fda-accepts-new-drug-application-for-triple-combination-tablet-for-adults-with-type-2-diabetes-300861030.html

    PR NEWSWIRE
    04 Jun 2019
    Share Share
    Jardiance sales ease Boehringer's patent-loss pain
    Jardiance sales ease Boehringer's patent-loss pain

    https://www.fiercepharma.com/pharma/jardiance-sales-boost-boehringer-ingelheim-s-revenue-2018

    Kyle Blankenship FIERCE PHARMA
    18 Apr 2019
    Share Share
    Zydus Pharms' Generic Linagliptin Receives Tentative Approval in US
    Zydus Pharms' Generic Linagliptin Receives Tentative Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208448

    FDA
    05 Dec 2018
    Share Share
    GLYXAMBI (empagliflozin/linagliptin) : Boehringer Ingelheim vs. Prinston Pharms
    GLYXAMBI (empagliflozin/linagliptin) : Boehringer Ingelheim vs. Prinston Pharms

    https://insight.rpxcorp.com/litigation_documents/13139439

    PATENT LITIGATION
    25 Nov 2018
    Share Share
    Jardiance (empagliflozin) : Boehringer Ingelheim vs. Annora Pharma
    Jardiance (empagliflozin) : Boehringer Ingelheim vs. Annora Pharma

    https://insight.rpxcorp.com/litigation_documents/13139442

    PATENT LITIGATION
    20 Nov 2018
    Share Share
    Jardiance (empagliflozin) & Glyxambi (empagliflozin/linagliptin) : Boehringer Ingelheim vs. Alkem Laboratories
    Jardiance (empagliflozin) & Glyxambi (empagliflozin/linagliptin) : Boehringer Ingelheim vs. Alkem Laboratories

    https://www.pharmacompass.com/pdf/news/jardiance-empagliflozin-glyxambi-empagliflozinlinagliptin-boehringer-ingelheim-vs-alkem-laboratories-1543987492.pdf

    PATENT LITIGATION
    07 Nov 2018
    Share Share
    Mylan's Generic Linagliptin;Metformin HCl Receives Tentative Approval in US
    Mylan's Generic Linagliptin;Metformin HCl Receives Tentative Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208430

    FDA
    03 Nov 2018
    Share Share
    ZydusPharms' Generic Linagliptin; Metformin HCl Receives Tentative Approval inUS
    ZydusPharms' Generic Linagliptin; Metformin HCl Receives Tentative Approval inUS

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208449

    FDA
    12 Oct 2018
    Share Share
    Zydus Cadila gets tentative USFDA nod for diabetes drug
    Zydus Cadila gets tentative USFDA nod for diabetes drug

    https://www.moneycontrol.com/news/business/zydus-cadila-gets-tentative-usfda-nod-for-diabetes-drug-3038641.html

    MONEY CONTROL
    11 Oct 2018
    Share Share
    Zydus Cadila gets tentative USFDA nod for diabetes drug
    Zydus Cadila gets tentative USFDA nod for diabetes drug

    https://www.moneycontrol.com/news/business/zydus-cadila-gets-tentative-usfda-nod-for-diabetes-drug-3038641.html

    MONEY CONTROL
    11 Oct 2018
    Share Share
    Zydus Cadila gets tentative USFDA nod for diabetes drug
    Zydus Cadila gets tentative USFDA nod for diabetes drug

    https://www.moneycontrol.com/news/business/zydus-cadila-gets-tentative-usfda-nod-for-diabetes-drug-3038641.html

    MONEY CONTROL
    11 Oct 2018
    Share Share
    Boehringer Ingelheim & Lilly present results of Tradjenta's CARMELINA® CV trial
    Boehringer Ingelheim & Lilly present results of Tradjenta's CARMELINA® CV trial

    https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-present-full-results-of-tradjentas-carmelina-cardiovascular-outcome-trial-300724218.html

    PR NEWSWIRE
    06 Oct 2018
    Share Share
    MSN Labs' Generic Linagliptin; Metformin HCl Receives Tentative Approval in US
    MSN Labs' Generic Linagliptin; Metformin HCl Receives Tentative Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208459

    FDA
    01 Oct 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Glyxambi 206073 (Empagliflozin and Linagliptin) Tablets
    FDA Confirms Paragraph IV Patent Challenge of Glyxambi 206073 (Empagliflozin and Linagliptin) Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-glyxambi-206073-empagliflozin-and-linagliptin-tablets-1538195835.pdf

    FDA
    29 Sep 2018
    Share Share
    PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties
    PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties

    https://www.prnewswire.com/news-releases/pdl-biopharma-acquires-depomeds-remaining-50-interest-in-royalties-and-milestones-on-type-2-diabetes-products-300691397.html

    PR NEWSWIRE
    02 Aug 2018
    Share Share
    BI, Lilly announce Trajenta’s cardiovascular outcome trial met primary endpoint
    BI, Lilly announce Trajenta’s cardiovascular outcome trial met primary endpoint

    https://www.businesswire.com/news/home/20180719005409/en

    BUSINESSWIRE
    19 Jul 2018
    Share Share
    Lupin, Boehringer expand collaboration for co-marketing of anti-diabetic drugs
    Lupin, Boehringer expand collaboration for co-marketing of anti-diabetic drugs

    http://www.pharmabiz.com/ArticleDetails.aspx?aid=109922&sid=2

    PHARMABIZ
    10 Jul 2018
    Share Share
    Hec Pharm USA Generic Linagliptin Receives Approval In US
    Hec Pharm USA Generic Linagliptin Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208335

    FDA
    25 May 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Jentadueto (Linagliptin & Metformin HCL) Extended-release Tablets
    FDA Confirms Paragraph IV Patent Challenge of Jentadueto (Linagliptin & Metformin HCL) Extended-release Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-jentadueto-linagliptin-metformin-hcl-extended-release-tablets-1527227322.pdf

    FDA
    23 May 2018
    Share Share
    Hec Pharm USA Generic Linagliptin;Metformin HCL Receives Approval In US
    Hec Pharm USA Generic Linagliptin;Metformin HCL Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208336

    FDA
    22 May 2018
    Share Share
    MSN Lab’s Generic Linagliptin Receives Approval In US
    MSN Lab’s Generic Linagliptin Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208457

    FDA
    25 Oct 2017
    Share Share
    Accord’s Generic Linagliptin;Metformin Hydrochloride Receives Approval In US
    Accord’s Generic Linagliptin;Metformin Hydrochloride Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208421

    FDA
    19 Oct 2017
    Share Share
    Teva Pharm’s Generic Linagliptin Receives Tentative Approval In US
    Teva Pharm’s Generic Linagliptin Receives Tentative Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208433

    FDA
    14 Sep 2017
    Share Share
    Aurobindo Pharma’s Generic Linagliptin Receives Approval In US
    Aurobindo Pharma’s Generic Linagliptin Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208415

    FDA
    20 Jun 2017
    Share Share
    Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at ADA
    Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at ADA

    https://www.dddmag.com/news/2017/06/boehringer-ingelheim-and-lilly-diabetes-alliance-present-33-abstracts-ada

    DDDMAG
    09 Jun 2017
    Share Share
    Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
    Merck and Pfizer prep for battle with SGLT2, combo diabetes filings

    http://www.fiercepharma.com/marketing/merck-and-pfizer-prep-for-battle-sglt2-combo-diabetes-filings

    Carly Helfand FIERCE PHARMA
    14 Mar 2017
    Share Share
    AZ gets US approval for diabetes combo Qtern
    AZ gets US approval for diabetes combo Qtern

    http://www.pmlive.com/pharma_news/az_gets_us_approval_for_diabetes_combo_qtern_1187741

    Phil Taylor PMLIVE
    01 Mar 2017
    Share Share
    AZ bounces back with diabetes combo win, but can it keep up with Lilly and BI?
    AZ bounces back with diabetes combo win, but can it keep up with Lilly and BI?

    http://www.fiercepharma.com/pharma/az-bounces-back-diabetes-combo-win-but-can-it-keep-up-lilly-and-bi

    Carly Helfand FIERCE PHARMA
    28 Feb 2017
    Share Share
    US OKs CV Death Risk Reduction Data for Empagliflozin
    US OKs CV Death Risk Reduction Data for Empagliflozin

    http://www.pharmatimes.com/news/us_oks_cv_death_risk_reduction_data_for_empagliflozin_1183336

    Selina McKee PHARMATIMES
    06 Jan 2017
    Share Share
    Lily's Jardiance Effective in Lowering Cardiovascular Death
    Lily's Jardiance Effective in Lowering Cardiovascular Death

    http://www.nasdaq.com/article/lilys-jardiance-effective-in-lowering-cardiovascular-death-cm709051?

    NASDAQ
    15 Nov 2016
    Share Share
    Pharma already balks at Germany's tough pricing regime
    Pharma already balks at Germany's tough pricing regime

    http://www.fiercepharma.com/pharma/already-a-hated-pricing-foe-germany-eyes-stiffer-limits-new-controls

    Tracy Staton FIERCE PHARMA
    14 Nov 2016
    Share Share
    Eleven medicines leap towards EU approval
    Eleven medicines leap towards EU approval

    http://www.pharmatimes.com/news/eleven_medicines_leap_towards_eu_approval_1136296

    Selina McKee PHARMATIMES
    19 Sep 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Linagliptin

    Access Virtual Booth

    Contact Supplier

    View Presentation

    JRS Linagliptin

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search